Trial Radar KI | ||
|---|---|---|
enums.trial_summary.trial_summary_welcome | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche
Medizinisches Zentrum City of HopeEat, Move, Live Program for the Reduction of Cancer and Chronic Disease Risk in Underserved Communities
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT05414396 ist eine interventionsstudie zur Untersuchung von Diabetes mellitus, Adipositasbedingter bösartiger Tumor und hat den Status aktiv, nicht rekrutierend. Die Studie startete am 20. März 2018 und soll 347 Teilnehmer aufnehmen. Durchgeführt von Medizinisches Zentrum City of Hope ist der Abschluss für 27. Oktober 2025 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 16. September 2025 aktualisiert.
Kurzbeschreibung
This clinical trial tests the Eat, Move, Live (EML) Program in reducing the risk of chronic diseases among underserved communities by improving healthy lifestyle practices, increasing physical activity and encouraging healthy eating behaviors. EML is a series of free culturally and linguistically appropriate nutrition and physical activity sessions. The interactive education segment of the EML Program is culturally responsive, and based on the community EML program, and topics will include: nutrition guidelines, reading food labels, recipe modification and healthy food preparation, eating healthy on a budget, chronic diseases information and prevention strategies. The EML program may help reduce the risk of cancer and chronic diseases by encouraging more physical activity and healthy eating behaviors.
Ausführliche Beschreibung
PRIMARY OBJECTIVES:
I. To evaluate program by assessing in combination with standard of care metformin: Changes in participants' knowledge, attitudes, and behavior.
II. To evaluate program by assessing in combination with standard of care metformin: Changes in body measurements.
III. To evaluate program by assessing in combination with standard of care metformin: Changes in biomarkers.
OUTLINE:
Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration.
Offizieller Titel
Reducing Cancer and Chronic Disease Risk in Underserved Communities: Eat, Move, Live Program
Erkrankungen
Diabetes mellitusAdipositasbedingter bösartiger TumorWeitere Studien-IDs
- 17410
- NCI-2022-00180 (Registerkennung) (CTRP (Clinical Trial Reporting Program))
- 17410 (Andere Kennung) (City of Hope Comprehensive Cancer Center)
- P30CA033572 (Zuwendung/Vertrag der US-NIH)
NCT-Nummer
Studienbeginn (tatsächlich)
2018-03-20
Zuletzt aktualisiert
2025-09-16
Studienende (vorauss.)
2025-10-27
Geplante Rekrutierung
347
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Aktiv, nicht rekrutierend
Primäres Ziel
Supportivtherapie
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellSupportive care (EML program) Participants attend EML program sessions weekly for 12 weeks including an educational session chronic disease risk reduction via nutrition and physical activity, a physical activity session, and a cooking/taste test demonstration. | Verhaltensintervention Attend EML program sessions Fragebogenverwaltung Ancillary studies |
Hauptergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Changes in attitudes and beliefs as measured by questionnaires from baseline to week 12 | Attitudes and beliefs regarding causes of diabetes asked in questionnaire, measured by endorsing one of the Likert-type scale values ranging from 1 (Agree) to 7 (Disagree). | Baseline and week 12 |
Changes in behavior as measured by questionnaires from baseline to week 12 | Behaviors related to food consumption asked in questionnaires, measured by endorsing one of "None", "1", "2-3", "4-6", "7 or more". | Baseline and week 12 |
Changes in height from baseline to week 12 | Height measured in meters | Baseline to 12 weeks |
Changes in weight from baseline to week 12 | Weight measured in Kilograms | Baseline to 12 weeks |
Changes in waist circumference from baseline to week 12 | Hip circumference measured in centimeters | Baseline to 12 weeks |
Changes in chest circumference from baseline to week 12 | Chest circumference measured in centimeters | Baseline to 12 weeks |
Changes in right upper arm circumference from baseline to week 12 | Right upper arm circumference measured in centimeters | Baseline to 12 weeks |
Changes in left upper arm circumference from baseline to week 12 | Left upper arm circumference measured in centimeters | Baseline to 12 weeks |
Changes in right upper thigh circumference from baseline to week 12 | Right upper thigh circumference measured in centimeters | Baseline to 12 weeks |
Changes in left upper thigh circumference from baseline to week 12 | Left upper thigh circumference measured in centimeters | Baseline to 12 weeks |
Changes in body fat percentage from baseline to week 12 | Body fat percentage measured in percent using a handheld BMI machine that calculates body fat percentage. | Baseline to 12 weeks |
Changes in systolic blood pressure from baseline to week 12 | Systolic blood pressure measured in mmHG | Baseline to 12 weeks |
Changes in diastolic blood pressure from baseline to week 12 | Diastolic blood pressure measured in mmHG | Baseline to 12 weeks |
Changes in hip circumference from baseline to week 12 | Hip circumference measured in centimeters | Baseline to 12 weeks |
Changes in biomarkers | Will be collected at baseline and follow up based on glycosylated hemoglobin (A1C) measuring guidelines. | Baseline to 12 weeks |
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
Akzeptiert gesunde Freiwillige
Ja
- Agrees to group consent at week 1
- Age over 18
- Able to speak and understand English and/or Spanish
- Don't agree to group consent at week 1
- Age younger than 18
- Not able to speak and understand English and/or Spanish
- Can't participate in physical activity
Medizinisches Zentrum City of Hope343 aktive klinische Studien zum ErkundenNationales Krebsinstitut, USA3039 aktive klinische Studien zum ErkundenKeine Kontaktdaten vorhanden
1 Studienstandorte in 1 Ländern
California
City of Hope Medical Center, Duarte, California, 91010, United States